NCT03530176View on ClinicalTrials.gov

18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes

NACompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

October 15, 2017

Study Completion Date

October 15, 2017

Conditions
AtherosclerosisComplications of Diabetes Mellitus
Interventions
RADIATION

18Fluoride-Sodium Fluoride radio-isotope

The investigators will be using 18F-NaF to image premature atherosclerosis in the coronary arteries of diabetic patients.

Trial Locations (1)

T6G 2B7

University Hospital of Alberta, Edmonton

All Listed Sponsors
lead

University of Alberta

OTHER

NCT03530176 - 18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes | Biotech Hunter | Biotech Hunter